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Glioblastomas (GBMs) are highly vascular and lethal
brain tumors that display cellular hierarchies contain-
ing self-renewing tumorigenic glioma stem cells
(GSCs). Because GSCs often reside in perivascular
niches and may undergo mesenchymal differentia-
tion, we interrogated GSC potential to generate
vascular pericytes. Here, we show that GSCs give
rise to pericytes to support vessel function and tumor
growth. In vivo cell lineage tracing with constitutive
and lineage-specific fluorescent reporters demon-
strated that GSCs generate the majority of vascular
pericytes. Selective elimination of GSC-derived peri-
cytes disrupts the neovasculature and potently
inhibits tumor growth. Analysis of human GBM spec-
imens showed that most pericytes are derived from
neoplastic cells. GSCs are recruited toward endothe-
lial cells via the SDF-1/CXCR4 axis and are induced
to become pericytes predominantly by transforming
growth factor b. Thus, GSCs contribute to vascular
pericytes that may actively remodel perivascular
niches. Therapeutic targeting of GSC-derived peri-
cytes may effectively block tumor progression and
improve antiangiogenic therapy.INTRODUCTION
Glioblastomas (GBMs) are fatal tumors with florid vascularization
that correlates with tumor malignancy and clinical prognosis
(Norden et al., 2009). Targeting endothelial cells (ECs) has
been a major focus of antiangiogenic therapeutics, although
tumor vessels consist of two distinct but interdependent cellular
compartments: ECs and pericytes (Bergers and Song, 2005;Carmeliet and Jain, 2011). However, most current therapies tar-
geting ECs are not curative and may transform tumor growth
pattern toward a more invasive phenotype in GBMs (Pa`ez-
Ribes et al., 2009), suggesting that targeting ECs alone is not
sufficient for effective tumor control. Therefore, further insights
into tumor vascular development and maintenance have direct
translational implications.
Vascular pericytes play critical roles in various physiological
contexts, including support of vascular structure and function,
maintenance of blood-brain barrier, facilitation of vessel matu-
ration, and initiation of vessel sprouting (Armulik et al., 2010;
Bell et al., 2010; Bergers and Song, 2005; Winkler et al.,
2011). Pericytes and ECs communicate with each other by
direct physical contact and reciprocal paracrine signaling to
maintain vessel integrity and function (Franco et al., 2011; Car-
meliet and Jain, 2011; Song et al., 2005). Altered association
between pericytes and ECs has been shown in tumor vessels
(Carmeliet and Jain, 2011; Winkler et al., 2011). Tumor vessels
with less pericyte coverage appear more vulnerable to radiation
and chemotherapy, suggesting that pericytes are critical to
protect ECs and may promote therapeutic resistance (Bergers
et al., 2003; Franco et al., 2011). When therapies target ECs in
tumors, the pericyte network often maintains a functional core
of pre-existing blood vessels (Carmeliet and Jain, 2011). The
tumor vasculature frequently exhibits structural and functional
abnormality with irregular pericytes on endothelial tubules.
The pericyte-EC interaction also differs substantially between
tumors and normal tissues (Morikawa et al., 2002; Winkler
et al., 2011). However, the mechanisms underlying the abnor-
mality and difference are poorly understood. To better under-
stand the vascular development and maintenance in tumors
and lay the foundation for improved targeting therapy, it is
essential to determine the interplay between cancer cells and
vascular compartments.
GBMs display remarkable cellular hierarchies with tumori-
genic glioma stem cells (GSCs) at the apex (Bao et al., 2006a;
Calabrese et al., 2007; Zhou et al., 2009), although the cancerCell 153, 139–152, March 28, 2013 ª2013 Elsevier Inc. 139
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stem cell (CSC) model remains controversial for some tumor
types (Magee et al., 2012). We previously demonstrated that
GSCs promote tumor angiogenesis through elevated expres-
sion of vascular endothelial growth factor (VEGF) (Bao et al.,
2006b). This study has been extended by others (Ehtesham
et al., 2009; Folkins et al., 2009). GSCs are often located in peri-
vascular niches and interact with ECs in a bidirectional manner
(Bao et al., 2006b; Calabrese et al., 2007). Within this context,
there was an excitement generated by reports suggesting that
GSCs may transdifferentiate into ECs (Ricci-Vitiani et al., 2010;
Soda et al., 2011; Wang et al., 2010). These reports have been
controversial because the frequency of GSC-EC conversion
was not defined, and ECs do not contain cancer genetic alter-
ations in human GBMs (Kulla et al., 2003; Rodriguez et al.,
2012). Because pericytes are physically proximal to ECs on
vessels, distinguishing ECs and pericytes by location alone
poses a challenge. A complementary or competing hypothesis
would be a lineage commitment of GSCs to vascular pericytes.
There are important reasons to consider GSCs as potential peri-
cyte progenitors. GSCs have the ability to undergo mesen-
chymal differentiation (deCarvalho et al., 2010; Ricci-Vitiani
et al., 2008). GSCs share properties with neural stem cells
(NSCs) that display the potential to transdifferentiate into peri-
cytes (Ii et al., 2009; Morishita et al., 2007). Further, pericytes
are similar to mesenchymal stem cells (MSCs) (Crisan et al.,
2008). Thus, we investigated the potential of GSCs to generate
vascular pericytes and contribute to the remodeling of perivas-
cular niches and determined the significance of GSC-derived
pericytes (G-pericytes) in maintaining functional vessels to
support GBM tumor growth.
RESULTS
GSCs Are Able to Assume a Pericyte Lineage In Vitro
To investigate a potential lineage link between GSCs and peri-
cytes, we initially examined the capacity of GSCs to differentiate
into pericytes in vitro. GSCs were isolated fromGBM tumors and
validated through functional assays (self-renewal, multipotency,
and tumor formation) as previously described (Bao et al., 2006a;
Guryanova et al., 2011). Immunofluorescent (IF) staining of
freshly sorted GSCs from primary GBMs and the GSC-gener-
ated tumorspheres demonstrated SOX2 expression but com-
plete absence of the pericyte markers a smooth muscle actin
(a-SMA) and NG2 (Figures S1A and S1B available online), sup-
porting a lack of contamination of GSC populations by pericytes.
After GSCs or tumorspheres were induced for differentiation, the
differentiated cells contained a fraction (4%–11%) of cells ex-
pressing multiple pericyte markers (a-SMA, NG2, CD248, and
CD146) (Figures S1C–S1E). To further determine GSC ability to
assume a pericyte lineage, we examined the cellular fate ofFigure 1. GSCs Have the Potential to Assume a Pericyte Lineage
(A) IF staining of SOX2 (a GSC marker) and a-SMA (a pericyte marker) in the sing
(B) IF staining of a-SMA and NuMA (a human cell-specific nuclear antigen) in dif
(C and D) In vivo lineage tracing of GSCswith GFP constitutive expression. Section
immunostained for CD31 to mark ECs and counterstained with DAPI. Arrows ind
(E) IF staining of CD31 in peritumoral brain adjacent to the GBM tumor derived f
All scale bars represent 25 mm. See also Figure S1.single GSC-derived tumorsphere that did not contain any cell ex-
pressing pericyte markers (Figure 1A). Upon differentiation, cells
derived from the single GSC-derived tumorsphere contained
a fraction of cells expressing pericyte markers (Figure 1B). To
rule out potential contamination of host-derived pericyte progen-
itors in xenograft-derived GSCs, we performed secondary
sorting of enriched GSCs with positive selection for the human
cell-specific surface antigen TRA-1-85 and negative selection
for the pericyte marker CD146. We confirmed that the single
GSC-generated spheres derived from the resorted GSCs
(SOX2+) did not contain any cell expressing pericyte markers
(Figure S1F), whereas differentiated cells derived from the single
GSC-derived sphere contained pericyte-marker-expressing
cells (Figure S1G). These pericyte-marker-positive cells also ex-
pressed the human-cell-specific nuclear antigen NuMA (Fig-
ure S1G), confirming that these pericytes were derived from
human GSCs, but not frommurine pericytes or their progenitors.
Collectively, these data demonstrate that GSCs have the
capacity to assume a pericyte lineage in vitro.
GSCsGiveRise to Vascular Pericytes inGBMXenografts
In Vivo
To extend the lineage analysis of GSCs in vivo, we examined the
origin of pericytes in GBM xenografts and found that pericytes
(CD146+CD248+; 2.63%–6.14% of total cells) sorted from the
xenografts were largely positive for human NuMA and TRA-1-
85 (Figures S1H, S1I, and S1L). In contrast, purified ECs
(CD31+CD105+) fromGBM xenografts were completely negative
for human NuMA and TRA-1-85 (Figures S1J–S1L). We then per-
formed a lineage tracing study by transducing GSCs with GFP
constitutive expression and implanted the GSCs orthotopically
to establish xenografts. Tumor sections of the xenografts
derived from the green fluorescent protein (GFP)-labeled GSCs
were immunostained for an EC marker (CD31) and several peri-
cyte markers (a-SMA, Desmin, NG2, CD146, CD248, Ang1,
CD13, and platelet-derived growth factor receptor b [PDGFRb])
because these pericyte markers are expressed in normal brain
and primary GBMs (Figures S2A–S2C). No tumor showed
GFP-positive ECs, but most tumor vessels were adorned with
GFP-positive cells with typical pericytic location and mor-
phology on the vascular external surface (Figures 1C and 1D).
IF analyses of pericyte markers further confirmed that expres-
sion of pericyte markers (Desmin, a-SMA, NG2, PDGFRb,
CD248, and CD146) overlapped with GFP in the majority
(mean 78%, range 57%–89%) of pericytes (Figures 2A and 2B;
Figures S2D and S2E), indicating that the majority of vascular
pericytes were derived from GSCs. We validated this result in
21 GBM xenografts using GFP-labeled GSCs isolated from 12
primary GBMs and 9 GBM xenografts, suggesting that the
contribution of GSCs to pericytes is a common event duringle GSC-derived tumorsphere. Nuclei were stained with DAPI.
ferentiated cells derived from the single GSC-derived tumorsphere.
s of GBM tumors derived from theGFP-labeled GSCs (D456 or CCF2170) were
icate GFP+ cells with pericytic location.
rom GFP-labeled GSCs (CCF2170).
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Figure 2. GSCs Generate Pericytes Expressing Specific Markers In Vivo
(A and B) In vivo lineage tracing of GSCs and IF staining of pericyte marker Desmin (A) or a-SMA (B) in GBM tumors derived from GFP-labeled GSCs (D456).
Quantifications show fractions of G-pericytes (GFP+ and Desmin+/a-SMA+).
(C) IF staining of Desmin in peritumoral brain adjacent to GBM tumor derived from GFP-labeled GSCs (CCF1468). A vessel containing G-pericytes (Desmin+ and
GFP+) in peritumoral brain was marked (#) and enlarged.
All scale bars represent 20 mm. The error bars represent SD. See also Figure S2.
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GBM growth. Notably, a minor fraction (mean 22%, range 11%–
43%) of vascular pericytes in theGBMxenografts did not overlap
with GFP expression, indicating that these pericytes were host
derived. Most tumor vessels had a mixture of GSC- and host-
derived pericytes (Figure 2A). Taken together, these data
demonstrate that GSCs have the capacity to generate the
majority of vascular pericytes in GBM xenografts.
Peritumoral Brain Vessels Contain G-Pericytes
Because GBMs commonly invade into normal brain, we exam-
ined whether GSCs contribute to vascular pericytes in peritu-
moral brain. We found that a subset of vessels in peritumoral
brain adjacent to the GFP-labeled GSC xenograft also contain
GFP-positive pericytes (Figure 1E). IF analyses validated a frac-
tion of vessels coexpressing pericyte markers and GFP and in
brain tissue near the GFP tumor (Figure 2C). These data indi-
cate that GSCs can also give rise to pericytes in the peritumoral
brain. Notably, G-pericytes (GFP+) were detectable not only in
peritumoral brain but also in tumor-free brain up to 0.86 mm
distant from the tumor edge, suggesting that GSCs were
recruited by ECs in the peritumoral brain to generate pericytes.
Thus, GSCs also generate vascular pericytes in the peritumoral
brain.
Validation of G-Pericytes by Lineage-Specific
Fluorescent Reporters
To provide direct evidence validating GSC capacity to generate
pericytes in vivo, we performed in vivo cell lineage tracing of
GSCs with a pericyte marker (Desmin or a-SMA) promoter-
driven expression of GFP or mCherry, which served as fluores-
cent reporters of pericyte lineage. We cloned the human
Desmin promoter (Li and Paulin, 1991) and a-SMA core
promoter (Keogh et al., 1999; Nakano et al., 1991) and then
generated lentiviral constructs for the Desmin promoter-driven
GFP expression (DesPro-GFP) or a-SMA promoter-driven
mCherry expression (aSMAPro-mCherry). We confirmed that
the cloned Desmin and a-SMA promoters were functional
and pericyte specific because GFP or mCherry expression
occurred specifically in human brain vascular pericytes
(HBVPs) (Figure S3A, left). We then implanted DesPro-GFP-
transduced GSCs into mouse brains and examined tumor
vessels by IF analysis. DesPro-driven GFP expression specifi-
cally marked perivascular cells that expressed pericyte
markers, including Desmin, NG2, PDGFRb, CD248, Ang1, and
CD13 (Figures 3A–3C), validating that GSCs generated vascular
pericytes in the GBM xenografts. The G-pericytes also ex-
pressed the gap junction protein connexin45 (Cx45) that is
often localized at pericyte-EC contacts (Figures 3D and 3E).
Notably, GFP-positive cells were mainly located in perivascular
regions close to vessels but rarely detected in regions distant
from vessels in tumors (Figure 3F). We further performed an
additional pericyte lineage tracing of GSCs cotransduced with
DesPro-GFP and aSMAPro-mCherry and detected coexpres-
sion of mCherry and GFP in perivascular cells (Figures 3G
and 3H). GFP+ perivascular cells were abundant around
vessels and the majority of pericyte-marker-positive cells
(>83%) expressed GFP (Figures 3A–3F), confirming that
GSCs generated the majority of pericytes in these tumors.Tumor pericytes often exhibit abnormal morphologies, some-
times extending their processes away from the endothelium
(Morikawa et al., 2002). The G-pericytes often displayed such
irregular morphology (Figures 3A and 3F). Recent appreciation
of intertumoral heterogeneity of GBMs has informed a mesen-
chymal subtype in contrast to proneural and classical subtypes
(Verhaak et al., 2010). Interestingly, in vivo lineage tracing
showed that mesenchymal GSCs have significantly greater
ability to generate pericytes than classic and proneural GSCs
in xenografts (Figures S3B and S3C; Table S1). Collectively,
these data provide direct evidence demonstrating that GSCs
have the capacity to generate pericytes in vivo.
Because our in vivo cell fate tracing of GSCs with GFP consti-
tutive expression failed to detect GSC-derived ECs (Figures 1C
and 1D), we performed the cell lineage tracing of GSCs with an
EC marker (CD31 or CD105) promoter-driven GFP expression
to directly address whether GSCs generate ECs. We cloned
the human CD105 (endoglin) promoter (Rı´us et al., 1998) and
the CD31 (PECAM-1) promoter restricted to ECs (Almendro
et al., 1996; Gumina et al., 1997) and then generated lentiviral
constructs for conditional GFP expression driven by CD31 or
CD105 promoter (CD31Pro-GFP or CD105Pro-GFP). We vali-
dated that the cloned CD31 and CD105 promoters were func-
tional and EC specific because CD31Pro- or CD105Pro-driven
GFP expression specifically occurred in ECs (human brain
microvessel endothelial cells [HBMECs]) (Figure S3A, right). To
perform EC lineage tracing of GSCs, GSCs with CD31Pro-GFP
or CD105Pro-GFP were orthotopically implanted into mouse
brains. In confirmation with our earlier studies, no GFP expres-
sion was detectable in tumor ECs marked by CD31 and Glut1
staining (Figures S3D and S3E), further ruling out the possibility
of GSC-derived ECs in GBM xenografts.
To further characterize the G-pericytes, we examined pericyte
marker expression in G-pericytes and HBVP pericytes. We
isolated G-pericytes by sorting GFP+CD146+ cells from GBM
xenografts derived from the DesPro-GFP-GSCs. Comparative
RT-PCR analyses of key pericyte markers (a-SMA, Desmin,
CD248, NG2, CD146, and PDGFRb) in the sorted G-pericytes
and HBVPs confirmed similar marker expression in the GBM
xenografts (Figure S4A). To address whether G-pericytes still
express GSC markers after lineage switching, we examined
expression of several putative GSC markers (SOX2, OLIG2,
CD133, and Nestin) and pericyte markers in sorted GSCs
(CD15+L1CAM+) and G-pericytes (GFP+CD146+). RT-PCR anal-
yses showed that G-pericytes no longer express the GSC
markers (Figure S4B). This result was confirmed by IF staining
of SOX2, OLIG2, or Nestin on frozen sections of the DesPro-
GFP-GSC xenografts. Consistently, GFP expression was turned
on specifically in perivascular cells that rarely (<0.8%) expressed
SOX2, OLIG2, or Nestin (Figure S4C, S4D, and S4F). In contrast,
the SOX2, OLIG2, or Nestin-expressing cells (GSCs) are local-
ized near perivascular niches (Figure S4C and S4D). The mutu-
ally exclusive expression of GSC and pericyte markers suggests
that GSCs undergo differentiation to generate G-pericytes rather
than being a GSC subpopulation adjacent to ECs in GBM
tumors. In addition, G-pericytes do not express astrocyte
markers such as glial fibrillary acidic protein (GFAP) and S100b
(Figures S4A, S4E, and S4F), indicating that G-pericytes areCell 153, 139–152, March 28, 2013 ª2013 Elsevier Inc. 143
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not a subpopulation of astrocytes. Consistently, pericytes and
astrocytes are distinct cell populations without overlapping
expression of specific markers in primary GBMs (Figure S4G).
These data demonstrate that G-pericytes are unique cells ex-
pressing specific pericyte markers.
Pericytes in Primary GBMs Are Commonly Derived from
Neoplastic Cells
To examine whether pericytes are lineage related to cancer cells
in human primary GBMs, we performed fluorescence in situ
hybridization (FISH) analyses of common GBM genetic changes
(Cancer Genome Atlas Research Network, 2008) in combination
with IF staining of a pericyte marker (a-SMA) to determine if peri-
cytes carry cancer genetic alterations in GBMs. Because gains
of chromosome 7 (EGFR amplification) or losses of chromosome
10 (PTEN loss) are frequent in GBM cells, permitting a lineage
tracing to the neoplastic cells, we employed DNA probes for
centromeres of chromosome 7 (CEP-7) and 10 (CEP-10),
EGFR, and PTEN to detect cancer genetic alterations in peri-
cytes, ECs, and tumor cells in GBM tissue microarrays. FISH
analyses showed the majority of tumor pericytes (mean 76%,
range 58%–83%) carried the same genetic alterations (CEP-7
polysomy, EGFR trisomy or amplification, CEP-10 loss, or
PTEN loss) as cancer cells in 49 GBMs (Figures 4A and 4B), indi-
cating that tumor pericytes are commonly derived from cancer
cells. In contrast, we rarely detected relevant genetic changes
in ECs in these GBMs (Figures S5A and S5B). To further confirm
these results, we isolated pericytes (CD146+CD248+; 2.18%–
5.26% of total cells) and ECs (CD31+CD105+) from primary
GBMs and performed similar FISH analyses. The majority
(>72%) of sorted tumor pericytes (a-SMA+) carried the same
genetic alteration (CEP-7 polysomy) as matched GSCs (Figures
4C and 4D). In contrast, sorted ECs (CD31+CD105+) expressed
Glut1 but did not share the GSC genetic alterations (Figure S5C
and S5D). These results support a tumor source for pericytes,
but not for ECs in human primary GBMs.
To further address whether pericytes in endogenous GBMs
are derived from cancer cells, we examined pericytes in the
genetically engineered mouse GBMs (Nestin-tva/Ink4a/Arf//
HA-PDGFB models; Hambardzumyan et al., 2009). IF staining
of hemagglutinin-tagged platelet-derived growth factor B (HA-
PDGFB) and pericyte markers (Desmin, NG2, CD248, or
a-SMA) showed that a significant fraction (mean 63%) of tumor
pericytes expressed HA-PDGFB, supporting a tumor origin (Fig-
ure 4E, 4F; data not shown). In contrast, staining of EC markers
(CD31 or Glut1) and HA-PDGFB showed no tumor-cell-derived
ECs in these mouse GBMs (Figure S5E). These data demon-
strate that pericytes in the genetically engineered mouse
GBMs are also largely derived from neoplastic cells.Figure 3. In Vivo Lineage Tracing of GSCs with Pericyte-Specific Prom
(A–F) In vivo lineage tracing of GSCs with Desmin promoter-driven GFP (Des
immunostained for an EC marker (CD31), a pericyte marker (Desmin, NG2, PDG
Quantifications show fractions of GFP+ pericytes (B), coverage by GFP+ pericyte
rare GFP+ pericytes away from vessels (F).
(G andH) In vivo lineage tracing of GSCswith coexpression of Desmin promoter-d
the fraction of GFP+ cells with mCherry.
All scale bars represent 25 mm. The error bars represent SD. See also Figures SSelective Elimination of G-Pericytes Disrupts Tumor
Vessels and Inhibits Tumor Growth
To determine the functional significance of G-pericytes, we
examined effects of selective elimination of G-pericytes on
vessels and tumor growth. GSCs were transduced with Des-
min-promoter-driven expression of herpes simplex virus thymi-
dine kinase (HsvTK) (Figure 5A) to achieve conditional HsvTK
expression in G-pericytes. Because HsvTK metabolizes ganci-
clovir (GCV) into a toxic agent specifically in cells expressing
HsvTK (Culver et al., 1992), G-pericytes expressing HsvTK
should be sensitive to GCV and thus eliminated by GCV treat-
ment. To confirm selective killing of G-pericytes expressing Des-
min-promoter-driven HsvTK by GCV treatment, we generated
a construct for coexpression of HsvTK and GFP under the
same promoter (DesPro-TK-GFP) (Figures 5A and S6A). As ex-
pected, after the DesPro-TK-GFP-transduced GSCs were
induced to differentiate, GFP was expressed in a fraction of
differentiated cells (G-pericytes) (Figure S6B). Apoptotic detec-
tion showed that GCV treatment selectively induced apoptosis
in cells coexpressing GFP and HsvTK (Figure S6C). These data
indicate that selective elimination of G-pericytes is achievable
by using Desmin-promoter-driven HsvTK conditional expression
with GCV treatment.
To examine the impact of selective targeting of G-pericytes on
tumor vessels, we implanted DesPro-TK-GFP-GSCs into mouse
brains. Mice bearing the tumors were treated with vehicle control
or GCV daily to induce HsvTK-mediated toxicity to G-pericytes.
Apoptotic detection by TUNEL staining demonstrated that GCV
treatment for 3 days selectively induced cell death in G-pericytes
(GFP+) in vivo (Figure 5B). Further, GCV treatment for 1 week
caused almost a complete depletion of G-pericytes, collapse
of vessel lumens, and disruption of endothelial walls in GBM
tumors (Figures 5C, 5D, S6D and S6E). Moreover, measurement
of vascular function by fluorescein isothiocyanate (FITC)-conju-
gated mega-dextran showed that GCV treatment for 1 week to
deplete G-pericytes severely attenuated vascular function in
the DesPro-TK-GSC xenografts, because perfusion of FITC-
mega-dextran into the tumorswas dramatically reduced (Figures
5E, 5F, S6F and S6G). Collectively, these data demonstrate that
selective elimination of G-pericytes potently disrupts vascular
structure and function in GBM tumors.
To evaluate the impact of selective targeting of G-pericytes on
tumor growth, we initially used subcutaneous tumor experiments
to track sequential tumor volumes. The established subcuta-
neous tumors derived from the DesPro-TK-GFP-GSCs were
treated with GCV or vehicle control for 3 weeks. GCV treatment
caused significant regression of the tumors (Figures 5G and 5H),
indicating that selective elimination of G-pericytes by HsvTK-
induced GCV toxicity inhibited tumor growth. To further validateoter-Driven Fluorescent Reporters
Pro-GFP). Sections of GBM tumors derived from DesPro-GFP-GSCs were
FRb, CD248, Ang1, or CD13) (A), or the pericyte-EC junction marker Cx45 (D).
s (C), or the fraction of GFP+ pericytes expressing Cx45 (E). An arrow indicates
rivenGFP and a-SMA promoter-drivenmCherry in GBMs. Quantification shows
3, S4, and Table S1.
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Figure 4. Pericytes Are Commonly Derived from Neoplastic Cells in Primary GBMs
(AandB)FISHanalysesofgeneticalterationswith theCEP-7,CEP-10,EGFR,orPTENprobe (in red) inpericytes (a-SMA+) inprimaryGBMs.Quantificationshowsaverage
fractions of pericytes carrying the cancer genetic alterations (CEP-7 polysomy, EGFR amplification or trisomy, CEP-10 loss, or PTEN loss) in GBM tissue arrays (B).
(C and D) FISH analyseswith CEP-7 probe in sorted pericytes (a-SMA+) andGSCs from primary GBMs. Quantification shows the fraction (mean 72%) of pericytes
carrying the GSC genetic alterations (D).
(E and F) IF staining of a pericyte marker (Desmin or a-SMA) and HA-PDGFB in the genetically engineered mouse GBMs (Nestin-tva/Ink4a/Arf//HA-PDGFB
model). Quantifications show fractions (mean 63%) of HA-PDGFB+ pericytes (F)
The scale bars represent 10 mm (A and C) and 25 mm (E). The error bars represent SD. See also Figure S5.
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this result in orthotopic tumors, we transduced GSCs either with
DesPro-GFP (control) or DesPro-TK and implanted these GSCs
into mouse brains to establish GBM xenografts. Both groups of
mice bearing the tumors were administered with GCV to elimi-
nate the G-pericytes expressing HsvTK. GCV treatment for
2 weeks caused extensive vessel regression in GBM tumors
derived from DesPro-TK-GSCs, but not from DesPro-GFP-
GSCs (Figures S6H and S6I). Moreover, GCV treatment for
3 weeks markedly inhibited intracranial tumor growth in GBM
xenografts derived from DesPro-TK-GSCs, but not in control
tumors from DesPro-GFP-GSCs (Figures 5I and 5J). Alterna-
tively, treatment by GCV, but not vehicle control suppressed
intracranial tumor growth in the GBM xenografts derived from
DesPro-TK-GSCs (Figure S6J). As a consequence, GCV treat-
ment significantly increased survival of animals implanted with
the DesPro-TK-GSCs (Figure 5K). These data demonstrate that
selective elimination of G-pericytes suppressed GBM tumor
growth and malignant progression.
GSCs Are Recruited toward ECs via the
SDF-1/CXCR4 Axis
To understand the mechanisms underlying GSC recruitment
toward ECs, we examined whether GSCs can be recruited by
HBMECs to support the maintenance of EC complexes in vitro.
GSCs labeled with the green fluorescent tracer CFSE were
mixed with HBMEC complexes labeled with the red fluorescent
tracer CMTRX. Integration of GSCs-derived cells into EC
complexes was detected on day 2 after cell mixing, and the
integration stabilized the EC complexes for extended periods
(2.6-fold) relative to EC complex alone (Figure 6A). To address
whether pericyte lineage specification of GSCs can be induced
by EC complexes, we cocultured GSCs with HBMECs and de-
tected integration of G-pericytes by a-SMA staining (Figure 6B).
Because the attachment of pericytes to ECs can be mediated
through adherens junctions containing N-cadherin (Gerhardt
et al., 2000), we examined N-cadherin expression and found
that N-cadherin was localized to the contact sites between
G-pericytes (a-SMA+) and EC complexes (Figure 6B).
To define the molecular mechanisms underlying GSC recruit-
ment by ECs, we analyzed the effect of several chemotactic
factors (SDF-1a, PDGFB, and transforming growth factor
b [TGF-b]) secreted by HBMECs on GSC migration. We found
that SDF-1 potently stimulated GSC migration (Figures S7A
and S7B), whereas PDGFB only modestly attracted GSCs. To
further address whether HBMECs attract GSCs via SDF-1, we
cocultured GSCs and HBMECs in separate chambers of trans-
wells and detected that HBMECs potently attracted GSCs, an
effect dependent on SDF-1 because an anti-SDF-1 antibody
attenuated the effects (Figures S7C and S7D). Because ECs in
brain and GBMs constitutively express SDF-1 (Kokovay et al.,
2010; Komatani et al., 2009), we confirmed that abundant
SDF-1 formed a gradient around vessels with greater SDF-1
proximal to vessels in brain and GBMs (Figure S7E).
Because SDF-1 is secreted by ECs and GSCs express the
SDF-1 receptor CXCR4 (Ehtesham et al., 2009; Folkins et al.,
2009), we hypothesized that brain ECsmay recruit GSCs at least
in part through the SDF-1/CXCR4 axis. CXCR4 knockdown in
GSCs reduced the recruitment of GFP-labeled GSCs to ECcomplexes (Figures 6C and 6D). In addition, an SDF-1 blocking
antibody significantly reduced the integration of GFP-labeled
GSCs into HBMEC complexes (Figures S7F and S7G). As
a further confirmation, we examined the effect of a CXCR4
inhibitor (AMD3100) on GSC recruitment to EC complexes.
AMD3100 treatment significantly reduced the integration of
GSCs (CMTRX labeled, in red) into CFSE-labeled HBMECs (in
green) (Figures S7H and S7I).
To further determine whether GSC recruitment to ECs
depends on the SDF-1/CXCR4 axis during tumor vasculariza-
tion, GFP-labeled GSCs were transduced with shCXCR4 or
nontargeting small hairpin RNA (shNT) and implanted intomouse
brains. In shNT xenografts, tumor vessels were covered with
abundant G-pericytes (GFP+ and Desmin+), whereas G-peri-
cytes and total pericyte coverage on vessels was significantly
reduced in shCXCR4 xenografts (Figures 6E–6G). Immunohisto-
chemical (IHC) staining confirmed that CXCR4 knockdown
significantly decreased vessel density in the tumors (Figures
S7J and S7K). Collectively, these data suggest that ECs recruit
GSCs via the SDF-1/CXCR4 axis and that targeting this pathway
reduces G-pericytes in GBMs.
TGF-b Induces Differentiation of GSCs into Pericytes
We next sought to understand the molecular mechanisms
underlying the pericyte lineage specification of GSCs. To identify
the potential factors inducing GSC differentiation into pericytes,
we examined the effect of several EC-secreted cytokines
(SDF-1, PDGFB, and TGF-b) on GSC differentiation into peri-
cytes. Immunoblot analysis showed that TGF-b dominantly
induced expression of a-SMA when GSCs were cultured in
differentiation media (Figures 7A and 7B). IF staining of multiple
pericyte markers (NG2, a-SMA, CD146 and CD248) confirmed
that TGF-b treatment increased the fraction of cells expressing
pericyte markers in the differentiated cells (Figures 7C and 7D;
data not shown). Further, TGF-b treatment induced GFP-
expressing cells in differentiated cells derived from DesPro-
GFP-GSCs (Figures 7E and 7F). To address whether ECs induce
GSC differentiation into pericytes through TGF-b, we cocultured
DesPro-GFP-GSCs and HBMEC complexes and monitored
GFP-expressing cells (G-pericytes) over time. GFP+ cells were
induced and integrated into EC complexes, an effect that was
attenuated by incubation of the EC complexes with an anti-
TGF-b antibody (Figure 7G). Immunoblot analysis validated
that coculture of GSCs with HBMECs or their conditioned media
induced expression of pericyte marker a-SMA in differentiated
cells, an effect that was reduced by a TGF-b neutralizing anti-
body (Figure 7H). Collectively, these data demonstrate that
HBMECs induce pericyte lineage specification of GSCs at least
in part through TGF-b. Thus, the recruitment of GSCs toward
ECs via the SDF-1/CXCR4 axis and the induction of GSC differ-
entiation into pericytes by TGF-b are two events controlled by
different molecular mechanisms (Figure 7I).
DISCUSSION
Pericytes play essential roles to maintain functional vessels to
support tumor growth. Tumor pericytes are thought to be
derived from their progenitors from the surrounding normalCell 153, 139–152, March 28, 2013 ª2013 Elsevier Inc. 147
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Figure 6. GSCs Are Recruited toward ECs
through the SDF-1/CXCR4 Axis to Support
Endothelial Complex
(A) In vitro endothelial complex formation of
HBMECs (labeled with red fluorescent tracer
CMTRX) with or without GSCs (labeled with CFSE,
in green).
(B) IF staining of a-SMA and N-cadherin in
complexes of HBMECs and GSC-derived cells.
Nuclei were stained with DAPI.
(C and D) Endothelial complexes of HBMECs with
GFP-labeled GSCs expressing shCXCR4 or shNT.
Quantification shows fractions of GSC-derived
cells (GFP+) on HBMEC complexes (D). *p < 0.001.
(E–G) In vivo lineage tracing of GSCs with GFP
constitutive expression and IF staining of CD31 or
Desmin in tumors derived from GSCs expressing
shCXCR4 or shNT. Quantifications show fractions
of G-pericytes (GFP+) (F) and total pericyte
coverage (G) on vessels. *p < 0.001.
The scale bars represent 100 mm (A–C) and
25 mm (E). The error bars represent SD. See also
Figure S7.tissue or from the bone-marrow-derived cells homing in tumors
after treatments (De Palma et al., 2005; Du et al., 2008). In this
study, we demonstrate that the majority of vascular pericytesFigure 5. Selective Elimination of G-Pericytes Disrupts Tumor Vessels and Inhibits Tumor Gro
(A) Schematic illustrations of Desmin-promoter-driven expression of HsvTK and coexpression of HsvTK and
(B) TUNEL assay detecting selective apoptosis (in red) of G-pericytes (GFP+) induced by ganciclovir (GCV) in
(CCF2170).
(C and D) IF staining of CD31 (in red) shows effects of selective elimination of G-pericytes (GFP+) by GCV on
GFP-GSCs. Quantification shows the reduced G-pericyte coverage by GCV treatment (D). *p < 0.001.
(E and F) Assessment of vascular function using the FITC-conjugated mega-dextran after selective elimin
DesPro-TK-GSCs. Quantification shows intensity of perfused FITC-mega-dextran into the control or GCV-tr
(G and H) The effect of targeting G-pericytes by GCV treatment on growth of subcutaneous tumors derived
mean tumor weights in the control and GCV-treated mice (H). *p < 0.001 (n = 12).
(I and J) The effect of selective elimination of G-pericytes on GBM growth in mouse brains. Mice bearing tumo
GSCs (control) were treated with GCV for 3 weeks. Images of whole brains (I) and histological analysis (hemato
are shown.
(K)Kaplan-Meier survival curvesofmicebearingGBMtumorsderived fromDesPro-TK-GSCsorDesPro-GFP-G
The scale bars represent 25 mm (B) and 100 mm (C and E). The error bars represent SD. See also Figure S6.
Cell 153, 139–15in GBMs are derived from GSCs.
Because G-pericytes express similar
pericytemarkers as normal brain vascular
pericytes, GSCs function as pericyte
progenitors and contribute to vasculature
formation in GBMs. The ability of GSCs to
generate vascular pericytes in vivo
suggests that GSCsmay actively remodel
their microenvironment and create a
supportive niche, permitting functional
vessels to augment tumor growth without
depending on the limited source of
normal pericyte progenitors from
surrounding tissues.
Because NSCs can transdifferentiate
into pericytes (Ii et al., 2009; Morishita
et al., 2007), a lineage link betweenNSCs and pericytes is present in normal tissues. Because
GSCs share regulatory programs with NSCs, the plasticity of
GSCs toward a pericyte lineage may be a product of aberrantwth
GFP.
GBM tumors derived from DesPro-TK-GFP-GSCs
vessels in GBM tumors derived from DesPro-TK-
ation of G-pericytes in GBM tumors derived from
eated tumors (F). *p < 0.001.
from DesPro-TK-GFP-GSCs. Quantification shows
rs derived from DesPro-TK-GSCs or DesPro-GFP-
xylin and eosin [H&E] staining) on brain sections (J)
SCs (control) afterGCV treatment. *p<0.001 (n=6).
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Figure 7. TGF-b Induces Differentiation of
GSCs into Pericytes
(A) Immunoblot (IB) analysis of pericyte marker
(a-SMA) expression in differentiated cells from
GSCs (CCF1992) in the presence of indicated
cytokines (1 ng/ml) in culture media.
(B) IB analysis of pericyte markers (a-SMA, CD248,
and NG2) and a GSC marker (SOX2) in GSCs and
differentiated cells with or without treatment of
TGF-b (2 ng/ml).
(C and D) IF staining of pericyte markers (NG2 and
a-SMA) in GSCs (CW1217) and differentiated cells
induced by serum or TGF-b. Quantification shows
pericyte fractions (D). *p < 0.001.
(E and F) In vitro pericyte lineage tracing of GSCs
with Desmin promoter-driven GFP induced by
serum or TGF-b (2 ng/ml). Quantification shows
fractions of GFP+ cells in the differentiated cells (F).
*p < 0.001.
(G) In vitro HBMEC complex formation with
DesPro-GFP-GSCs in the presence of anti-TGF-
b antibody (monoclonal antibody [mAb]) or immu-
noglobulin G (IgG).
(H) IB analysis of a-SMA expression after coculture
of GSCs with HBMECs or their conditioned media
in the presence of anti-TGF-b antibody or IgG.
(I) A schematic illustration showing the recruitment
of GSCs toward ECs and the differentiation of
GSCs into pericytes in GBMs. GSCs expressing
CXCR4 are recruited toward ECs by SDF-1 and in-
duced predominantly by TGF-b to become peri-
cytes to support vessel function and tumor growth.
The scale bars represent 25 mm (C and E) and
100 mm (G). The error bars represent SD.developmental biology. Although previous reports suggest that
GSCs may give rise to ECs in GBMs (Ricci-Vitiani et al., 2010;
Soda et al., 2011; Wang et al., 2010), such an event may be
very rare because ECs in GBMs rarely carry the cancer genetic
mutations as demonstrated in our study and others (Kulla et al.,
2003; Rodriguez et al., 2012). Moreover, our complementary
lineage tracing studies failed to demonstrate GSC-derived ECs
in vivo, although in the culture condition we occasionally
observed rare EC-marker-expressing cells (<0.6%) in differenti-
ated cells fromGSCs. Because vascular pericytes closely attach
to ECs and both cells appear very thin, prior studies may have
missed the true identity of tumor-derived cells on vessels.
Because both ECs and pericytes express Tie2 (De Palma et al.,
2005), the use of Tie2 promoter-driven HsvTK expression for tar-
geting ‘‘GSC-derived ECs’’ (Ricci-Vitiani et al., 2010) might actu-
ally eliminate the G-pericytes. Our in vivo lineage tracing with
pericyte- or EC-specific promoter-driven fluorescent reporters150 Cell 153, 139–152, March 28, 2013 ª2013 Elsevier Inc.directly demonstrated that GSCs give
rise to pericytes rather than ECs in vivo.
The contribution of GSCs to vascular
pericytes requires GSC recruitment
toward ECs. Because ECs in brain and
GBMs express abundant SDF-1 forming
chemoattractant gradient, the expression
of CXCR4 (the receptor for SDF-1) inGSCs (Ehtesham et al., 2009; Folkins et al., 2009) may provide
a paracrine loop for recruitment of GSCs toward ECs. A recent
study showed that NSCs can be recruited to perivascular niches
in normal brain through the CXCR4/SDF-1 axis (Kokovay et al.,
2010). The recruitment of pericyte progenitors to ECs in normal
tissues also depends on SDF-1/CXCR4 signaling (Song et al.,
2009). SDF-1 expression has been proposed as one of the
mechanisms underlying the resistance to antiangiogenic therapy
in GBM trials (Batchelor et al., 2007). Elevated SDF-1 signaling
may enhance GSC recruitment toward ECs and increase G-peri-
cyte coverage to protect tumor vessels, leading to resistance to
antiangiogenic therapy.
The potent capacity of GSCs to generate vascular pericytes
allows active vascularization in GBMs to support tumor growth.
Because GSCs contribute to the majority of vascular pericytes in
GBMs, G-pericytes may have a crucial role in mediating thera-
peutic resistance in GBMs. Because pericytes juxtacrine to
ECs express significant levels of VEGF and other factors to
support EC survival (Franco et al., 2011; Song et al., 2005; Win-
kler et al., 2011), G-pericytes may protect ECs and render ECs
less responsive to antiangiogenic agents in GBMs. Thus, target-
ing G-pericytes may synergize with current therapies targeting
ECs to achieve more effective outcome. Because CSCs are
present in other solid cancers (Magee et al., 2012), it is important
to determine whether CSCs can generate vascular pericytes in
other malignant tumors with florid angiogenesis. Our studies
demonstrate that GSCs not only interact with perivascular
niches but also have the capacity to remodulate their microenvi-
ronment by contributing pericyte compartments of the neovas-
culature. Because selective elimination of G-pericytes potently
disrupted vessels and inhibited tumor growth, therapeutic tar-
geting of G-pericytesmay have a significant impact on improving
GBM treatment efficacy.
EXPERIMENTAL PROCEDURES
Isolation of GSCs and Non-Stem Tumor Cells from GBMs
GBM surgical specimens were collected in accordance with a Cleveland Clinic
Institutional Review Board-approved protocol. GSCs and non-stem tumor
cells were derived from GBM tumors and functionally validated as described
previously (Bao et al., 2006a; Guryanova et al., 2011). For the detailed proce-
dure, please see Extended Experimental Procedures.
Pericyte or EC-Specific Promoter-Driven Expression of GFP or
mCherry
Human Desmin promoter (312 bp) with an enhancer (284 bp) (Li and Paulin,
1991), a-SMA promoter (262 bp) with an enhancer (123 bp) (Keogh et al.,
1999; Nakano et al., 1991), CD105 promoter plus enhancer (955 bp) (Rı´us
et al., 1998), and CD31 promoter plus enhancer (887 bp) restricted to ECs
(Almendro et al., 1996; Gumina et al., 1997) were cloned by PCR and
confirmed by sequencing. The specific promoter with enhancer was inserted
into pCDH-CMV-EF1-Puro lentiviral vector (System Biosciences) to replace
the original CMV promoter. The ORF of GFP or mCherry was then inserted
into the vector to generate lentiviral constructs. Lentiviruses were produced
and tittered as described elsewhere (Guryanova et al., 2011).
Cell Lineage Tracing of GSCs
To perform cell lineage tracing, GSCs were transduced with GFP or mCherry
constitutive expression or conditional expression driven by the pericyte or
EC-specific promoter through lentiviral infection and then transplanted into
brains of athymic BALB/c nu/nu mice to establish xenografts as described
elsewhere (Guryanova et al., 2011). To trace cell lineage of GSCs in vivo,
sections of mouse brains bearing the xenografts were immunostained for
pericyte or EC markers and analyzed for GFP or mCherry expression. IF
and IHC stainings were performed as described (Guryanova et al., 2011).
Tumor sections of the genetically engineered mouse GBMs were provided
by Dr. Dolores Hambardzumyan. For detailed methods and the antibody infor-
mation, please see Extended Experimental Procedures.
Selective Targeting of G-Pericytes in GBM Xenografts
GSCs were transduced with Desmin or CD31-promoter-driven expression of
HsvTK, GFP, or HsvTK plus GFP through lentiviral infection and then trans-
planted into brains of athymic mice. Mice bearing the xenografts received
GCV (Sigma-Aldrich) at 75 mg/kg/day or vehicle control daily through intraper-
itoneal injection. The xenografts were collected for IF and IHC staining and
fluorescent analysis. To evaluate the targeting effect on animal survival,
mice were maintained until the development of neurological signs.
HBVPs, HBMECs, and EC Complex Formation
HBVPs and HBMECs were obtained from ScienCell. HBMECs with low
passage were used for coculture and endothelial complex formation assaysas described (Bao et al., 2006b). For the detailed procedure and the labeling
of GSCs and HBMECs, please see Extended Experimental Procedures.
Statistical Analysis
All quantified data were statistically analyzed. Grouped data are presented as
mean ± SD. The difference between experimental groups was assessed by
one-way ANOVA or one-way ANOVA on ranks testing. For the animal survival
experiments, log-rank survival analysis was performed.
For further details, please see Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and one table and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2013.02.021.
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